Abstract
To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat β-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC50 value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat β3-adrenoceptors. The EC50 values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat β1-adrenoceptors and were sumless and 0.1 for β2-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC50 value of 290 nmol/L. The concentration–response curve of mirabegron was affected neither by the β1-adrenoceptor selective antagonist CGP-20712A nor by the β2-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of β3-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.
Similar content being viewed by others
References
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Kerrebroeck PV, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178
Andersson K-E, Arner A (2004) Urinary bladder contraction and relaxation physiology and pathophysiology. Physiol Rev 84:935–986
Athanasopoulos A, Giannitsas K (2011) An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 816342
Chapple C, Wyndaele JJ, Van Kerrebroeck P, Radziszewski P, Dvorak V, Boerrigter P (2010) Dose-ranging study of once-daily mirabegron (YM-178) a novel selective β3-adrenoceptor agonist in patients with overactive bladder (OAB). Eur Urol Suppl 9:249
de Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 41:691–721
Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, Strosberg AD, Largis EE, Dutia MD, Bloom JD (1994) β3 Adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269:1000–1006
Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, Kobayayashi M, Yamaguchi O (1999) Expression and possible functional role of the β3-adrenoceptor in human and rat detrusor muscle. J Urol 161:680–685
Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore K, Hooper R, McEwan AJB, Triscott J (1994) Cerebral aetiology of urinary urge incontinence in elderly people. Age Ageing 23:246–250
Hegde SS, Mammen M, Jasper JR (2004) Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Investig Drugs 5:40–44
Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson K-E (1999) Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819–825
Igawa Y, Aizawa N, Homma Y (2010) Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 51(12):811–818
Ishiura Y (1996) Experimental study of voiding dysfunction induced by cerebral infarction in rats. Jpn J Urol 87:1221–1230
Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, Akahane S, Miyata H, Ajisawa Y, Nishizawa O, Andersson K-E (2002) Effects of selective β2 and β3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 168:1247–1252
Khan Z, Starer P, Yang WC, Bhola A (1990) Analysis of voiding disorders in patients with cerebrovascular accidents. Urology 35:265–270
Khullar V, Cambronero J, Stroberg P, Angulo J, Boerrigter P, Blauwet MB, Wooning M (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder—results from a European-Australian Phase III trial. Eur Urol Suppl 10:278–279
Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC (2001) Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community based survey. Urology 57:1044–1050
Liggett SB (1992) Functional properties of the rat and human β3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42:634–637
Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84–91
Madersbacher H, Halaska M, Voigt R, Höfner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646–651
Michel MC, Sand C (2009) Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 27:711–715
Michel MC, Ochodnicky P, Homma Y, Igawa Y (2011) β-Adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 131:40–49
Nakada Y, Yokoyama O, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, Nagasaka Y, Namiki M (2000) Effects of aniracetam on bladder overactivity in rats with cerebral infarction. J Pharmacol Exp Ther 293:921–928
Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N (2011) The efficacy and safety of mirabegron in patients with overactive bladder syndrome—results from a North-American Phase III trial. Eur Urol Suppl 10:278
Pehrson R, Stenman E, Andersson K-E (2003) Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur Urol 44:495–499
Suzuki M, Ohtake A, Yoshino T, Yuyama H, Hayashi A, Ukai M, Okutsu H, Noguchi Y, Sato S, Sasamata M (2005) Effect of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol 512:61–66
Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of (R)-2-(2-Aminothiazol-4-yl)-4-{2-[(2-hydroxy-2- phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647
Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S (1999) Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367–1373
Tsuchida S, Noto H, Yamaguchi O, Itoh M (1983) Urodynamic studies on hemiplegic patients after cerebrovascular accident. Urology 21:315–318
Uchida H, Shishido H, Nomiya M, Yamaguchi O (2005) Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via β-adrenoceptors. Eur J Pharmacol 518:195–202
Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. doi:10.1111/j.1464-410X.2012.11023.x
Yamaguchi O (2002) β3-adrenoceptors in human detrusor muscle. Urology 59(Suppl 5A):25–29
Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y (1998) Species differences in the distribution of β-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol 124:593–599
Yokoyama O, Yoshiyama M, Namik M, de Groat WC (1999) Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol Regul Integr Comp Physiol 276:935–942
Yokoyama O, Yoshiyama M, Namiki M, de Groat MC (2002) Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats. Exp Neurol 173:129–135
Acknowledgments
The authors are grateful to Dr. Cees Korstanje (Astellas Pharma Europe B.V.) for helpful comments and suggestions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hatanaka, T., Ukai, M., Watanabe, M. et al. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn-Schmiedeberg's Arch Pharmacol 386, 247–253 (2013). https://doi.org/10.1007/s00210-012-0821-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-012-0821-4